Is it safe to give a patient with anorexia nervosa who is having seizures from electrolyte abnormalities and is not receiving gabapentin bupropion (Wellbutrin) extended‑release 300 mg?

Bupropion is Absolutely Contraindicated in This Patient

Do not prescribe Wellbutrin (bupropion) 300 mg XL to this patient with anorexia nervosa who is experiencing seizures from electrolyte abnormalities. This represents a clear-cut contraindication with potentially life-threatening consequences.

FDA Contraindications Are Explicit and Non-Negotiable

The FDA labeling for Wellbutrin XL explicitly lists "current or prior diagnosis of bulimia or anorexia nervosa" as an absolute contraindication 1. This is not a precaution or warning—it is a black-box level contraindication that prohibits use in this population.

Additionally, the FDA label contraindications include "seizure disorder" 1, and this patient is actively experiencing seizures, making bupropion doubly contraindicated.

Multiple Compounding Risk Factors Create Extreme Danger

This clinical scenario presents a perfect storm of seizure risk:

Active Seizure Activity

• The patient is currently having seizures due to electrolyte abnormalities 1
• Bupropion is dose-dependently epileptogenic, with seizure risk increasing at higher doses 1
• The 300 mg XL dose requested is at the higher end of therapeutic dosing, further elevating seizure risk 2

Anorexia Nervosa as a Specific Risk Factor

• Patients with anorexia nervosa have a 4-fold increased risk of bupropion-induced seizures compared to the general population 2
• In one case series, all bupropion-related seizures occurred at therapeutic doses (≤450 mg/day), with eating disorders identified as a significant risk factor 2
• Severe bupropion abuse has been documented in patients with bulimia nervosa, resulting in grand mal seizures at doses of 3,000-4,500 mg/day 3

Electrolyte Disturbances

• Anorexia nervosa commonly causes chloride-responsive metabolic alkalosis and other electrolyte abnormalities 4
• Electrolyte abnormalities themselves lower seizure threshold 5
• The combination of bupropion (which lowers seizure threshold) plus existing electrolyte-induced seizures creates multiplicative risk 1

Absence of Seizure Prophylaxis

• The patient is not taking gabapentin or any other antiepileptic medication 1
• The FDA label explicitly contraindicates bupropion with "abrupt discontinuation of antiepileptic drugs" 1
• Without seizure prophylaxis, there is no protective buffer against bupropion's epileptogenic effects

Clinical Evidence Demonstrates Real-World Harm

Multiple case reports document severe outcomes:

• Grand mal seizures have occurred with bupropion XR even at therapeutic doses 6
• Bupropion accounts for 1.4% of all new-onset seizures presenting to emergency departments, making it the third leading cause of drug-related seizures after cocaine and benzodiazepine withdrawal 2
• At 300 mg/day, the seizure incidence is approximately 1 in 1,000 patients treated—but this risk is substantially higher in patients with eating disorders 7
• Seizures in eating disorder patients have multiple etiologies including electrolyte abnormalities (10.7%), substance withdrawal (18.7%), and Wernicke's encephalopathy (4%) 5

Alternative Treatment Approach

The 2023 American Psychiatric Association guidelines for eating disorders recommend:

• For anorexia nervosa: Eating disorder-focused psychotherapy as first-line treatment, NOT antidepressant medication 8
• Comprehensive metabolic panel including electrolytes must be obtained and corrected 8
• ECG monitoring is recommended in patients with restrictive eating disorders 8

Immediate Management Priorities

1. Correct electrolyte abnormalities causing the current seizures 8, 5
2. Initiate appropriate seizure management per emergency protocols 8
3. Consider alternative antidepressants if depression treatment is needed—SSRIs like fluoxetine are recommended for bulimia nervosa but have limited evidence in anorexia nervosa 8
4. Refer for eating disorder-focused psychotherapy as the evidence-based treatment for anorexia nervosa 8

Critical Pitfalls to Avoid

• Never override FDA contraindications for convenience or patient preference—these exist because of documented mortality risk 1
• Do not assume lower doses are safe—seizures have occurred at all therapeutic doses in eating disorder patients 2
• Do not prescribe bupropion for appetite suppression or weight control in eating disorder patients, as this represents dangerous misuse 3
• Screen for eating disorder history before prescribing bupropion to any patient 2, 9